Trichomoniasis: Diagnosis, Treatment, and Drug Resistance
Course Description
Course Title: Trichomoniasis: Diagnosis, Treatment, and Drug Resistance
Course Duration: 1 hour.
Course Description:Trichomoniasis is the most common non-viral sexually transmitted disease in the United States and worldwide. While it has sometimes been considered of low consequence to patients’ health, newer information suggests it can contribute to increased susceptibility to other infections. It is also thought to contribute to adverse outcomes of pregnancy. The presentation will cover Identification and management of drug resistant infections.
Course Objectives: At the conclusion of this program, the participant will be able to:
- Discuss how to assess Trichomonas vaginalis infections.
- Describe the treatment of Trichomonas vaginalis infections.
- Explain the process to seek treatment for patients with drug resistant infections or for individuals with hypersensitivity.
Target Audience: This basic-level webinar is for laboratory professionals.
Access Requirements: To participate in this webinar, you will need a computer with internet access and speakers or a headphone to hear the audio. To test your system, visit: https://admin.acrobat.com/common/help/en/support /meeting_test.htm
Special Needs: Course content is closed captioned where applicable and optimized for a screen reader.
CEUs: The Centers for Disease Control and Prevention, Laboratory Training and Services Branch, is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
This webinar is approved for 1.0 hour of P.A.C.E.® credit, and has been approved for 1.0 contact hours in the General (Microbiology/ Mycology/ Parasitology) category for Florida Laboratory Licensees.
P.A.C.E.® Course#: 288-005-17 Florida Course#: 20-563855
Links and Files
For more information on Continuing Education (CE) credit types and details, please visit the CDC Laboratory Training Continuing Education page.
- Page last reviewed: July 26, 2016
- Page last updated: July 26, 2016
- Content source: